Clinical Trial

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Objectives:To evaluate the safety and tolerability of BAT8008 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-11-09.
Status change: Not Yet Recruiting → Recruiting 2026-02-04
Trial Details
NCT Number NCT05620017
Lead Sponsor Bio-Thera Solutions
Conditions Advanced Solid Tumors
Enrollment 182 participants
Start Date 2022-11-30
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-09